Pilomatricoma (pilomatrixoma)

Definition, overview and nomenclature

Pilomatricoma — also called pilomatrixoma and historically the calcifying epithelioma of Malherbe (after the French pathologist Jean Malherbe, who first described it in 1880 as a "calcified epithelioma of sebaceous glands") — is a common, benign skin appendage tumour arising from the hair-matrix (matrical) cells of the hair bulb.[1] It is now recognised as the single most common tumour of the hair follicle encountered in clinical practice, and the most frequent adnexal tumour excised in children.

The lesion is, in essence, a small calcified pellet in the dermis or superficial subcutis. Its dominant clinical sign is stony-hardness: on palpation a pilomatricoma feels like a bead or grain of rice buried in the skin. The calcification that produces this hardness is also the key to its histological identity — the tumour is one of the very few cutaneous nodules in which ghost (shadow) cells and calcium deposits are found together.[6]

Historical note

Malherbe and Chenantais described the lesion in 1880 as a "calcified epithelioma of sebaceous glands", believing the tumour arose from sebaceous epithelium — hence the lingering term "epithelioma". The hair-matrix (matrical) origin was established only in the mid-twentieth century by Forbis and Helwig (1961), who renamed the entity pilomatrixoma; the now-preferred term pilomatricoma follows from that work. The molecular era opened in 1999, when Chan and colleagues identified the activating CTNNB1 mutation as the causal event.[6] This historical arc — from "sebaceous epithelioma" to "hair-matrix tumour" to "Wnt-pathway neoplasm" — is itself a favourite viva question.

A typical clinical vignette

A parent brings a 6-year-old girl to clinic having noticed a hard lump on her right cheek that has been present for "a few months" and is slowly growing. On examination there is a skin-coloured, 1 cm, stony-hard, deep-seated nodule with a faint bluish tint, fixed to the overlying skin but mobile over the cheek. There is no punctum. Stretching the skin reveals an angular, multi-faceted shape (tent sign), and pressing one pole tilts the other (teeter-totter sign). The diagnosis is pilomatricoma, confirmed on excision biopsy, which shows basaloid matrical cells, ghost cells and calcification. The lesion is enucleated under local anaesthetic and does not recur. This vignette captures virtually every high-yield fact about the condition.[3]

Despite the historical name "epithelioma", pilomatricoma is not a carcinoma — it is benign, and its molecular driver (an activating mutation in CTNNB1) is shared with a family of cutaneous adnexal tumours showing matrical differentiation (matricoma, pilomatrical carcinoma, melanocytic matricial tumour).[6][7]

Classification and variants

Pilomatricoma is usually described as a single clinicopathological entity, but several morphological variants are recognised and are examiner-favourite differentials:[1][2]

The malignant counterpart, pilomatrix carcinoma, is classified separately (see Complications and Specific subtypes).[10]

Epidemiology and risk factors

Pilomatricoma is common. It accounts for a significant fraction of the benign adnexal lesions excised in children, and is the most common hair-follicle tumour in patients under 20 years.[1][8]

Age. There are two peaks: a dominant peak in the first two decades of life (most cases presenting between ages 3 and 18), and a smaller second peak in adults over 50 (often head-and-neck lesions). The paediatric predominance is the single most useful epidemiological clue at the bedside.[8]

Sex. A modest female predominance (approximately 3:2) is consistently reported.[8]

Multiplicity. Roughly 2–10% of patients have more than one lesion. Multiple pilomatricomas — especially when familial, numerous, or appearing in atypical sites — should prompt a search for an associated syndrome.[4]

Risk factors / associations. The dominant "risk factor" is the presence of a germline or somatic Wnt-pathway abnormality. Patients with the syndromes listed below have a markedly elevated likelihood of developing multiple pilomatricomas.[4]

Pathophysiology — from beta-catenin to calcification

The molecular story of pilomatricoma is one of the cleanest in cutaneous pathology. In 1999 Chan and colleagues showed that pilomatricomas harbour activating mutations in CTNNB1, the gene encoding beta-catenin — a landmark paper establishing that a common human skin tumour is caused by a single, recurrent oncogenic pathway.[6] The follow-up confirmed the finding across a series of lesions.[7]

The Wnt–beta-catenin axis and hair-matrix differentiation

In a normal hair follicle, Wnt signalling stabilises beta-catenin, which translocates to the nucleus, partners with LEF/TCF transcription factors, and switches on the gene programme that drives hair-matrix (matrical) cells to differentiate into the hair shaft. This pathway is normally tightly regulated and switched off once the hair cycle moves on.[6]

In pilomatricoma, a somatic activating mutation in CTNNB1 (most often affecting the serine-threonine phosphorylation sites in exon 3) renders beta-catenin resistant to proteasomal degradation. The protein accumulates, translocates to the nucleus constitutively, and permanently switches on the matrical-differentiation programme of the cell.[6][7]

The cellular consequence is a tumour that tries — and fails — to make hair. The proliferating basaloid (matrical) cells at the periphery of the tumour nest attempt matrical differentiation, but instead of producing a hair shaft they keratinise aberrantly into anucleate eosinophilic squames — the ghost (shadow) cells that define the lesion histologically.[6]

Why the lesion calcifies

Ghost cells are mummified, anucleate keratinising cells that retain the eosinophilic outline of the lost nucleus. They are calcium-avid: calcium salts deposit within and around the dead cells, producing the dystrophic calcification that gives the tumour its stony-hard consistency. In long-standing lesions, ossification (true bone formation) may supervene.[1]

The full histogenetic cascade can therefore be drawn as a single chain:[8]

Inflammation and rupture

When a pilomatricoma is traumatised or partially ruptures, ghost cells and calcified material extrude into the dermis, provoking a foreign-body giant-cell granulomatous reaction. This is the pathological basis of the inflamed, tender, occasionally infected clinical presentation that brings a child to the doctor. The same mechanism explains the perforating variant, in which the calcified material is transepidermally eliminated.[2]

Clinical presentation

The clinical picture is so characteristic that an experienced clinician can make the diagnosis at the bedside in most cases. The triad of age + site + consistency is the key.[3]

Morphology

The lesion is a deep-seated, firm to stony-hard subcutaneous nodule, usually 0.5–3 cm in diameter. The overlying skin is most often skin-coloured, but characteristically shows a faint blue or bluish-grey tint (the calcified material shining through the thinned dermis). There is no punctum (distinguishing it from an epidermoid cyst). The nodule is typically fixed to the overlying skin but mobile over deeper structures.[6]

Named bedside signs

The teeter-totter sign is the most specific of the bedside manoeuvres: because the tumour is a rigid calcified mass sitting in a dermal pocket, downward pressure on one pole tilts the opposite pole down too, like a seesaw.[1] The tent sign is more sensitive but less specific — stretching the skin flattens it over the angular facets of the lesion.

Site distribution

Lesions favour the head, neck and upper extremities:[8]

Symptoms and course

Most pilomatricomas are asymptomatic and are brought to medical attention by a parent who has noticed a hard lump. A minority are mildly tender. The lesion grows slowly over months to years and never regresses spontaneously. Some lesions become acutely inflamed (red, swollen, tender) — this reflects rupture with foreign-body reaction and sometimes secondary bacterial infection.[3]

Atypical presentations

The anetodermic/bullous variant presents as a soft, wrinkled, occasionally bullous pouch of skin overlying the calcified nodule (due to elastolysis); the perforating variant presents with a crusted, umbilicated surface discharging chalky material.[2]

Differential diagnosis

Because pilomatricoma is stony-hard, calcified and subcutaneous, its differential is narrow but contains several high-yield mimics. The discriminating features are worth memorising.[7]

The single most discriminating bedside test is the combination of stony hardness + no punctum + a child: epidermoid cysts (the commonest mimic) are softer and punctate; everything else is either softer, in the wrong age group, or has a different surface.[8]

The stony-hard nodule — a focused approach

When the bedside question narrows to "is this hard nodule a pilomatricoma or something else?", three categories of mimic must be actively excluded in turn. The keratinous cysts (epidermoid, pilar/trichilemmal) are distinguished by their punctum (epidermoid only) and their softer, doughy consistency — they yield slightly under the finger, whereas a pilomatricoma does not. The true calcifications (calcinosis cutis, osteoma cutis, miliary osteoma post-acne) deposit calcium in a different pattern — calcinosis cutis forms discrete white hard grains or plaques within the skin rather than a single encapsulated tumour, and osteoma cutis is almost always multiple and follows a history of acne on the face. The soft-tissue neoplasms (dermatofibroma, BCC, juvenile xanthogranuloma, lipoma, keloid) are excluded on consistency and context: a dermatofibroma sits in the dermis (not beneath it), dimples on lateral compression, and favours the legs; a BCC is superficial, pearly and telangiectatic with a tendency to central ulceration; a lipoma is soft and sub-fascial rather than dermo-subcutaneous.[4]

Dermoscopy narrows the differential

Where the clinical picture is ambiguous, dermoscopy helps separate pilomatricoma from its mimics. The white and white-blue structureless areas of pilomatricoma (calcification) overlap partly with the white structureless areas of a molluscum or a keratoacanthoma, but pilomatricoma lacks the multifocal globules of molluscum and the central keratin and hairpin vessels of a keratoacanthoma. The reddish homogeneous zones and irregular linear vessels of pilomatricoma are, importantly, not the arborising (tree-like) telangiectasia of a basal cell carcinoma and not the crown vessels of sebaceous hyperplasia.[9]

Clinical and bedside assessment

The diagnosis is made on clinical examination in the majority of cases, supplemented by dermoscopy and ultrasound where doubt exists.[4]

• Inspection in good light. Look for the faint blue-grey tint and the angular multi-faceted shape when the skin is stretched (tent sign). Confirm there is no punctum.
• Palpation. Establish the stony-hard consistency and that the nodule is fixed to skin, mobile over deep tissues. Elicit the teeter-totter sign (press one pole, the other dips).
• Dermoscopy. Characteristic features include white and white-blue structureless areas (calcification), reddish homogeneous areas (vascular component), and irregular vessels at the periphery.[9]
• Syndrome screen (if multiple). Look for the stigmata of Gardner syndrome (osteomas, epidermoid cysts, pigmented ocular fundus lesions), myotonic dystrophy (percussion myotonia, frontal balding, cataracts), Rubinstein-Taybi (broad thumbs/halluces, facial dysmorphism) and Turner syndrome.[4][5]
• History. Establish the tempo (slow growth over months–years is typical; rapid growth flags carcinoma), the age of onset, the number of lesions, any family history of polyposis/colon cancer, myotonia or developmental disorder, and any cosmetic concern. Ask about preceding trauma or acne (osteoma cutis) and about ulceration, bleeding or discharge (carcinoma, perforating variant).
• Palpation technique. Examine the lesion between thumb and forefinger in two planes. A pilomatricoma is non-compressible — it does not dimple or yield. Confirm fixity to overlying skin (the tumour tethers the dermis) but mobility over deep fascia; a lesion fixed to deep structures is not a pilomatricoma and demands imaging. Compare with the contralateral side for symmetry.
• Photography and documentation. Record the lesion's size, site and appearance before excision; this is especially valuable in the paediatric setting and for medico-legal and scar-assessment purposes.

The clinical scoring question

Examiners commonly frame the bedside assessment as: "This child has a hard lump on the cheek — what is your differential and how do you confirm it?" The expected answer walks through the three-step discriminator (punctum, hardness, age) to a confident clinical diagnosis of pilomatricoma, with dermoscopy as the first-line adjunct and excision biopsy as both confirmatory and therapeutic. Imaging is reserved for deep, parotid-region, or diagnostically uncertain lesions.[1]

Investigations

The histological features are:[1][2]

1. Basaloid (matrical) cells — small, deeply basophilic cells with hyperchromatic nuclei at the periphery of the tumour islands; they recapitulate the matrical cells of the hair bulb.
2. Ghost (shadow) cells — anucleate eosinophilic squames retaining the outline of the lost nucleus; the single most diagnostic cell. They are "mummified" keratinising cells.
3. Calcification — dystrophic calcium within and between ghost cells; gives the lesion its stony hardness.
4. Ossification — mature bone formation in long-standing lesions.
5. Foreign-body giant-cell granuloma — a reaction to extruded ghost-cell material.
6. Cystic change — central cavitation (pseudocystic variant).[2]

When and how to exclude pilomatrix carcinoma

Histology of a typical pilomatricoma shows orderly matrical maturation. Pilomatrix carcinoma instead shows atypia, frequent mitoses, deep invasion and an infiltrative growth pattern, and tends to present with a rapidly enlarging, large (>3 cm), recurrent or ulcerated mass.[10] Any lesion displaying these features must be reviewed by an experienced dermatopathologist. A diagnostic pitfall is fine-needle aspiration cytology, which can be misread as carcinoma because isolated atypical basaloid cells resemble malignant squames; tissue architecture (the orderly basaloid-to-ghost-cell transition) is needed.

Immunohistochemistry and the family of matrical tumours

Pilomatricoma sits within a family of cutaneous tumours showing matrical (hair-matrix) differentiation, all linked by the same Wnt–beta-catenin biology. Recognising the family clarifies the differential of an "adnexal tumour with ghost cells":[6][7]

The molecular hallmark is shared: nuclear beta-catenin immunostaining in the basaloid cells (reflecting the stabilising CTNNB1 mutation) confirms matrical differentiation and helps separate these tumours from basal cell carcinoma and squamous-cell carcinoma, which show only membranous beta-catenin.[7] In routine practice, however, standard H&E histology is diagnostic and molecular testing is reserved for atypical, recurrent or diagnostically difficult lesions.

Management

Principle

Pilomatricoma is benign but does not regress spontaneously. Surgical excision is the definitive treatment and is curative when the lesion is completely removed.[1] There is no role for topical agents, intralesional corticosteroid, cryotherapy or laser.

Stepwise surgical approach

Enucleation versus elliptical excision — technique in detail

The choice of technique depends on depth, skin adherence and the cosmetic unit. For a small, superficial, non-adherent lesion — the typical cheek nodule of a child — an enucleation is preferred. A short (2–4 mm) incision is made over the lesion along a relaxed skin-tension line; the dermis is bluntly dissected off the hard white capsule; and the calcified mass is delivered by gentle pressure from either side (it often 'pops out' intact). The skin edges are closed with a single suture or adhesive. This technique minimises scar length and is particularly valued on the face.[1]

For a deeper lesion, one that is firmly tethered to the overlying skin, or a recurrent/atypical lesion, an elliptical excision is appropriate. A vertical or fusiform ellipse oriented along the relaxed skin-tension line removes the tumour together with the overlying skin to which it is adherent, ensuring a complete margin. The defect is closed in layers (deep dermal sutures then epidermal closure). An atypical or recurrent lesion should never be enucleated — it must be excised with a margin and fully submitted for histology to exclude pilomatrix carcinoma.[10]

Parotid- and preauricular-region lesions deserve special respect: an incision here must be planned to avoid the facial nerve branches, and pre-operative ultrasound should confirm the diagnosis before any cut is made. If the lesion proves to lie within the parotid substance rather than in the skin, referral to a head-and-neck or parotid surgeon is warranted rather than proceeding blind.[3]

The acutely inflamed or infected lesion

An inflamed/ruptured pilomatricoma should be settled first with a short course of an oral antibiotic active against skin flora (for example, flucloxacillin 250–500 mg orally four times daily for 5–7 days in an adult; weight-based paediatric dosing — e.g. flucloxacillin 12.5–25 mg/kg four times daily), with definitive excision deferred until the inflammation has settled, to reduce the risk of a hypertrophic facial scar.[1]

Observation

In a child with a classic, asymptomatic, confidently diagnosed lesion, observation is acceptable — particularly if there are anaesthetic concerns. Excision is then timed for convenience (e.g. under a single general anaesthetic with another planned procedure). Parents should be told the lesion will not resolve on its own.[8]

Multiple pilomatricomas and syndromic associations

Multiple pilomatricomas (two or more lesions) are uncommon but important because they are a cutaneous flag for several genetic syndromes. A single pilomatricoma needs no further work-up, but a patient with multiple lesions, an unusual site, or a positive family history should be screened.[4]

Familial multiple pilomatricoma (without an overt syndrome) is rare and typically autosomal dominant, with activating CTNNB1-related biology in keeping with the somatic mutations found in solitary lesions.[4]

Why Gardner syndrome matters most

Of all the syndromic associations, Gardner syndrome (a phenotypic variant of familial adenomatous polyposis, FAP) carries the highest stakes. The triad of epidermoid cysts, osteomas and pilomatricomas is one of the earliest cutaneous markers of the disease, often appearing years or decades before the colonic polyposis declares itself. Because the polyposis progresses inevitably to colorectal carcinoma (typically by the fourth decade if untreated), a child presenting with multiple pilomatricomas and a family history of early-onset colon cancer must be referred for APC gene testing and surveillance colonoscopy according to the relevant regional guidance (e.g. from adolescence in confirmed APC carriers). This is the single instance in which a benign-looking skin lump is a sentinel for a potentially lethal visceral disease, and it is the reason the multiplicity red flag exists.[4]

Myotonic dystrophy — the anaesthetic trap

Myotonic dystrophy type 1 (DM1, DMPK CTG-repeat expansion) is the second classic association. The relevance to the dermatologist is twofold: first, multiple pilomatricomas can be a presenting clue in a child who later develops myotonia; and second, anaesthetic safety. Patients with DM1 are exquisitely sensitive to anaesthetic agents and may develop postoperative myotonia, respiratory depression, or malignant hyperthermia-like reactions, and suxamethonium can precipitate sustained myotonic rigidity. Any patient with known or suspected DM1 undergoing excision must have a dedicated anaesthetic review before surgery.[5]

Syndromic screening workflow

Specific subtypes and scenarios

• Pseudocystic pilomatricoma. Clinically fluctuant, mimics an epidermoid cyst; ultrasound may show a cyst-like cavity, but histology reveals the diagnostic basaloid + ghost-cell pattern.[2]
• Anetodermic / bullous pilomatricoma. Overlying skin is atrophic or bullous (elastolysis); favours the shoulders of children; dermoscopy shows the bulla overlying the calcified core.
• Giant pilomatricoma. Lesions over 3 cm (sometimes over 5 cm) raise the differential of pilomatrix carcinoma and demand histology with wide sampling.[10]
• Parotid-region pilomatricoma. Presents as a preauricular or angle-of-mandible mass; mimics a parotid neoplasm. Ultrasound first — the calcified target lesion with acoustic shadowing is diagnostic and avoids unnecessary parotid surgery. Excision must respect the facial nerve plane.[3]
• Pilomatrix carcinoma. The rare malignant counterpart (<1%); presents as a rapidly enlarging, large, ulcerated or recurrent dermal/subcutaneous mass, often of the scalp, face or upper back of an adult. Managed by wide local excision (a 1–2 cm margin where feasible) with expert dermatopathology; nodal and metastatic disease can occur, so long-term follow-up is required.[10]

Complications and pitfalls

Prognosis and disposition

Pilomatricoma is benign. Complete surgical excision is curative, with a recurrence rate of 0–3% when the lesion is fully removed; recurrence indicates incomplete excision and should prompt re-excision and review of the histology.[1]

Malignant transformation of a previously typical pilomatricoma into pilomatrix carcinoma is exceedingly rare; carcinoma more often arises de novo. Any lesion that recurs or grows rapidly after excision must be regarded with suspicion.[10]

Follow-up. A typical, completely excised pilomatricoma needs no routine follow-up other than a wound check. Atypical lesions (large, recurrent, carcinoma on histology) require dermatology/surgical oncology follow-up.[9]

Patient and parent counselling. Reassure the family that the lesion is entirely benign and that excision is curative. Explain that the lesion will not disappear on its own and that the calcified material is the reason it feels so hard. Discuss the expected scar honestly — particularly for facial lesions — and the importance of sun protection to minimise post-inflammatory pigmentation. Set the expectation that a single, complete excision is curative and that recurrence is rare (<3%). If the diagnosis is syndromic, counsel about the implications of the underlying syndrome and the need for family screening.[4]

Disposition. Most pilomatricomas are managed in the primary-care or dermatology/surgical day-case setting. Referral to a paediatric dermatologist, paediatric surgeon, or oculoplastic/head-and-neck surgeon is warranted for facial/periorbital/parotid lesions, large or atypical lesions, multiple lesions (syndromic work-up), or any lesion where the diagnosis is in doubt.[3]

Special populations

• Children. The dominant group. Plan incisions along relaxed skin tension lines; consider general anaesthesia or sedation for facial lesions; counsel parents about the scar and the benign nature of the lesion. Avoid unnecessary excision of asymptomatic classic lesions if anaesthetic risk is non-trivial.
• Paediatric surgical detail. In a young child, the enucleation technique (a 2–3 mm incision over the lesion, blunt dissection, and shelling-out of the calcified mass) is preferred to elliptical excision because it produces a smaller scar. A topical local-anaesthetic cream (e.g. eutectic lidocaine/prilocaine applied under occlusion for 30–60 minutes) reduces injection pain. For periorbital lesions, an ophthalmology / oculoplastic opinion is advisable given the proximity to the globe and the thin eyelid skin. Where multiple lesions need excision, batch them under a single general anaesthetic.
• Infants. Lesions are uncommon under 12 months; when present, observation is usually preferred unless the diagnosis is in doubt or the lesion is ulcerated, because the anaesthetic risk and the scar are disproportionate to the benign lesion.
• Patients with Gardner syndrome (FAP). A child with multiple pilomatricomas and a family history of polyposis needs urgent colonoscopy and APC testing — the cutaneous lesion can predate the development of colon cancer by years, and early surveillance is life-saving.
• Myotonic dystrophy. Anaesthetic implications are significant — myotonia is worsened by cold, shivering, suxamethonium and certain inhalational agents; involve an anaesthetist early.[5]
• Darker phototypes. Higher risk of post-inflammatory hyperpigmentation and keloidal scarring after excision; counsel accordingly and use meticulous technique.
• Pregnancy / immunosuppressed. Pilomatricoma behaviour is unchanged; excision can usually be deferred until after pregnancy if asymptomatic.

Evidence, guidelines and regional differences

What the evidence does — and does not — settle

The molecular biology of pilomatricoma is unusually well established: the 1999 Chan paper showed that the same class of stabilising CTNNB1 mutations drives the tumour, placing pilomatricoma in the same Wnt-pathway family as other matrical tumours and providing the rationale for the nuclear beta-catenin immunostain used in difficult cases.[6][7] The dermoscopic signature (white and white-blue structureless areas with reddish zones) was codified by Zaballos in 2008 and remains the accepted pattern.[9] The clinical epidemiology — paediatric predominance, head-and-neck site bias, and female predominance — was confirmed in the Hassan paediatric series.[8]

What the evidence does not settle is (i) whether routine pre-operative ultrasound is cost-effective for a confidently diagnosed lesion (opinion varies; most surgeons excise on clinical grounds alone); (ii) the optimal margin for pilomatrix carcinoma (a 1–2 cm margin is broadly recommended but is not evidence-based in randomised trials);[10] and (iii) the true rate of malignant transformation of a typical pilomatricoma (quoted at well under 1%, but never precisely measured in a population study). These uncertainties should be acknowledged honestly with patients and in viva answers.

Regional deltas

Exam pearls and high-yield minutiae

Exam application bank (NEET-PG / INICET)

One-line answer

Pilomatricoma is the commonest benign skin appendage tumour of hair-matrix (matrical) cells, presenting as a firm, stony-hard, calcified, deep-seated subcutaneous nodule on the face, neck or upper extremities of children and young adults. Histology: basaloid (matrical) cells + ghost (shadow) cells + calcification. Driven by activating CTNNB1 (beta-catenin) mutations. Treatment is surgical excision. Multiple pilomatricomas flag Gardner syndrome (FAP), myotonic dystrophy, Rubinstein-Taybi, Turner and Apert.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard.[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes.[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change.[3]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each.[3]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory.[3]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Pilomatricoma (pilomatrixoma).